Short answer
Crinetics Pharmaceuticals, Inc. (CRNX) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Crinetics reported financial results for the period ended June 30, 2026.
Crinetics Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Crinetics reported financial results for the period ended June 30, 2026
- Full results and management commentary available in Exhibit 99.1
- Press release furnished under Item 2.02, limiting Exchange Act Section 18 liability
Item EX-99.1 · Exhibit EX-99.1
- Vertex acquisition at $85.00 per share, approximately $10.0B equity value, expected closing in Q3 2026 subject to approvals
- PALSONIFY net product revenue $24.0M, up from $10.3M in Q1 2026, signaling accelerating commercial adoption
- 70%+ of PALSONIFY patients on reimbursed therapy, reducing near-term access risk for the commercial launch
- Q2 revenue $25.1M versus $1.0M prior-year, while net loss reached $120.9M amid $99.9M R&D and $57.6M SG&A
- Cash, cash equivalents and investments totaled $1.2B at June 30, 2026, supporting operations through the proposed transaction process
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Crinetics Pharmaceuticals, Inc. 8-K filings
Get the next CRNX 8-K as it lands
Follow CRNX for push alerts, or ask the research agent what this filing means.